Aurinia Pharmaceuticals heads into the back half of August with a modest positioning divergence worth watching: short sellers have been trimming exposure over the past month while options traders have quietly tilted more bullish than usual.
The clearest shift this week is in options sentiment. The put/call ratio has dropped to 0.68 — more than one standard deviation below its 20-day average of 0.71 — placing it near the more bullish end of its recent range and well off the 52-week high of 0.88. That move has been steady rather than sudden; the PCR has drifted lower every session since early August, suggesting a gradual rotation into calls rather than a one-day positioning spike. The direction of travel is unmistakably less defensive than it was a month ago.
Short interest reinforces that tone, though the picture is nuanced. Bears hold roughly 6.9% of the free float short — a meaningful level for a biotech — but that position has shrunk around 8% over the past month, pulling back from above 10 million shares in mid-July to just over 9.1 million now. The week-on-week reading ticked up slightly (+0.6%), so the covering trend has not been uniform. Crucially, the borrow market offers no signal of stress: availability is running at over 1,000% — meaning there are roughly ten shares available to borrow for every one currently lent out — and the cost to borrow has fallen 20% this week to just 0.42%. With borrow this loose and this cheap, there is no mechanical pressure forcing shorts to cover. The short score of 50.9 sits squarely in neutral territory.
The Street is cautiously constructive but not pushing aggressively. The most recent analyst action came from RBC Capital on August 7, when Douglas Miehm lifted his target from $15 to $16 while keeping a Sector Perform rating — a small upgrade in conviction, not a conviction call. The mean target across the desk sits at $17, implying roughly 11% upside to the current price of $15.30. Bulls point to a long runway for LUPKYNIS, with revenue projections climbing steeply toward $930 million by 2033 alongside an emerging contribution from aritinercept. Bears flag the slow pace of patient uptake, a crowded autoimmune landscape, and ongoing operating losses that keep the long-term funding question open. EPS surprise ranks in the 73rd percentile, a sign the company has been managing expectations well. The P/E multiple of 15x and EV/EBITDA of 7.5x are both edging lower over the past month — modest multiple compression, not a collapse.
On the ownership side, the most structurally interesting holder is Tang Capital Management, which controls nearly 10% of shares and added aggressively in late May and early June — buying over 800,000 shares in a cluster of trades around $15.28, just pennies below where the stock trades today. That buying has not continued into August based on the available data, but Tang's concentrated position and board seat make it a meaningful signal of insider-level conviction at current prices. BlackRock added roughly 350,000 shares as recently as late July, and Two Sigma built a position of 1.5 million shares in Q1.
Earnings are not due until early November, so the near-term catalyst calendar is relatively quiet. The next print is therefore less about whether LUPKYNIS is growing and more about whether the pace of new patient starts shows any inflection — the metric the Street has been watching closely as the debate between the bull and bear cases plays out.
See the live data behind this article on ORTEX.
Open AUPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
